摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Methyl-3-[2-(3,5-dimethoxyphenyl)-2-oxoethyl]-1H-imidazolium bromide | 103793-33-5

中文名称
——
中文别名
——
英文名称
1-Methyl-3-[2-(3,5-dimethoxyphenyl)-2-oxoethyl]-1H-imidazolium bromide
英文别名
1-(3,5-Dimethoxyphenyl)-2-(3-methylimidazol-3-ium-1-yl)ethanone;bromide
1-Methyl-3-[2-(3,5-dimethoxyphenyl)-2-oxoethyl]-1H-imidazolium bromide化学式
CAS
103793-33-5
化学式
Br*C14H17N2O3
mdl
——
分子量
341.205
InChiKey
DWRVIGCMUWSQEZ-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.78
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    44.3
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • 3-(2-Aryl-2-oxoethyl)-imidazolium salts as hypoglycemic agents
    申请人:ELI LILLY AND COMPANY
    公开号:EP0182533A2
    公开(公告)日:1986-05-28
    The invention relates to imidazolium salts which are effective in lowering blood glucose levels in mammals. In particular, there is provided a compound of formula (I) which is useful in lowering blood glucose levels: in which: R1 is C1-C4 alkyl; R2 and R3, independently, are hydrogen or C1-C4 alkyl; each R4, independently is, -OR5, -NR6R7, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, or C1-C4 alkylthio; R5 is hydrogen or R6 is hydrogen, C1-C4 alkyl, or -C-R8; R7 is hydrogen or C1-C4 alkyl; each R8, independently, is C1-C4 alkyl or phenyl; Z is oxygen or sulfur; X is a therapeutically acceptable anion; and m is 0, 1 or 2.
    本发明涉及可有效降低哺乳动物血糖水平的咪唑盐。 特别是提供了一种有助于降低血糖水平的式 (I) 化合物:其中: R1为C1-C4烷基;R2和R3独立地为氢或C1-C4烷基;每个R4独立地为-OR5、-NR6R7、C1-C4烷基、C1-C4烷氧基、三氟甲基或C1-C4烷硫基;R5为氢或R6为氢、C1-C4烷基或-C-R8;R7为氢或C1-C4烷基;每个R8独立地为C1-C4烷基或苯基;Z为氧或硫;X为治疗上可接受的阴离子;m为0、1或2。
  • Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides
    作者:Samuel J. Dominianni、Terence T. Yen
    DOI:10.1021/jm00130a013
    日期:1989.10
    Blood glucose levels in viable, yellow, obese, diabetic mice are reduced following oral administration of phenacylimidazolium halides. Compounds 2 and 3 produced reductions of ca. 40% 2 h after doses of 100 mg/kg po. Since these mice do not respond to sulfonylureas, the glucose-lowering activity of phenacylimidazolium salts in this model suggests a mechanism other than that of stimulating insulin secretion. Only phenacylimidazolium halides with electron-donating groups were active; other azolium salts or variations in the phenacyl portion (alterations in the keto function; chain lengthening or extensive branching) produced inactive compounds.
  • ——
    作者:DOMINIANNI S. J.、 YEN T. T.
    DOI:——
    日期:——
  • US4609670A
    申请人:——
    公开号:US4609670A
    公开(公告)日:1986-09-02
  • US4683312A
    申请人:——
    公开号:US4683312A
    公开(公告)日:1987-07-28
查看更多